Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

EASL 2021: Rapid Recap by Dr. Stefan Zeuzem

June 23-26, 2021; Virtual

Hear a rapid update of the top HBV, HCV, and HDV studies from the Virtual 2021 International Liver Congress, 2021.

Stefan Zeuzem, MD
Released: July 22, 2021

Information on this Educational Activity

Faculty

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine I
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, Intercept, Janssen, Novo Nordisk, and Sobi and fees for non-CME/CE services from AbbVie, Gilead Sciences, and MSD.

Staff

Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no relevant conflicts of interest to report.
Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B Stacy, PharmD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment

person default Carla Coffin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 21, 2022 Expired: June 20, 2023

Clinical Care Options (CCO) commentary with advice for healthcare professionals from a person who had end-stage liver failure from a missed HCV diagnosis

person default Sherry Tierney Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 17, 2022 Expired: May 16, 2023

Clinical Care Options (CCO) commentary from Maria Buti, MD, on the interplay between HBV infection and pregnancy

Maria Buti, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 18, 2022 Expired: April 17, 2023
Educational grant provided by:
AbbVie
Antios Therapeutics
Gilead Sciences, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings